Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
Recruiting · NCT06862856
Conditions: Prostate Cancer (Adenocarcinoma), Prostate Specific Antigen
At a glance
- Research payments reported, 2025
- $45,875
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 50
About the trial
- Sponsor
- Massachusetts General Hospital (with Blue Earth Diagnostics)
- Tested
- Positron Emission Tomography (PET) (diagnostic_test)
- Dates
- Started 2025-05-20; completion 2026-12-01
- Results posted
- Not yet
The purpose of this study is to assess detection rate of flotufolastat F 18 positron emission tomography (PET) for low prostate specific antigen (PSA) recurrence of prostate cancer (PC) following radical prostatectomy.
From ClinicalTrials.gov, last updated 2026-05-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Blue Earth Diagnostics reported $45,875 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.